TRAIL shows potential cardioprotective activity. Invest New Drugs 2012;30(3):1257-60.
. . .
Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets. Mol Cell Endocrinol 2011;331(1):136-42.
. Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes. Mol Cell Endocrinol 2014;394(1-2):13-20.
. .
.
Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients. BMC Nephrol 2017;18(1):219.
.